AMIX

Business Context and Reporting Period

Company: Autonomix Medical, Inc. (AMIX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended March 31, 2026
Business Overview: Autonomix is a development-stage medical device company focused on a catheter-based platform for sensing and treating disorders of the nervous system. The technology utilizes a "sense, treat, verify" approach, integrating high-sensitivity neural signal detection with targeted radiofrequency (RF) ablation. The company is currently in the proof-of-concept stage, initially targeting the treatment of pain associated with pancreatic cancer. It has no approved products and has not generated any product revenue to date.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company has no debt outstanding as of March 31, 2026.

Material Changes vs. Prior Period

• Increased Operating Expenses: Total operating expenses rose 47% to $17.0 million from $11.6 million.
  • R&D Expenses: Increased 51% to $7.1 million, driven by higher clinical trial and product development costs and a $0.4 million increase in stock-based compensation.
  • G&A Expenses: Increased 44% to $9.9 million, primarily due to a $2.2 million increase in stock-based compensation (related to option cancellations) and higher legal/professional fees.
• Stock-Based Compensation Acceleration: The company accelerated the recognition of $3.7 million in stock-based compensation expense in 2026 following the cancellation of stock options for certain employees and board members in exchange for severance agreements.
• Capital Structure Changes: Significant equity financing activities occurred, including the issuance of pre-funded warrants and Series C warrants in November 2025, and warrant inducements in July 2025. The company converted remaining convertible notes into common stock in March 2025, resulting in zero interest expense for 2026.
• Cash Position: Cash reserves decreased by approximately $2.1 million year-over-year despite $10.2 million in financing proceeds, due to increased operational burn.

Guidance, Outlook, Risks, and Unusual Items

Outlook and Guidance

• Liquidity: Management estimates current cash resources are sufficient to fund operations into, but not beyond, the fourth calendar quarter of 2026.
• Capital Needs: The company estimates it will require an additional $25 million to $32 million to fund operations through an initial commercial launch.
• Clinical Strategy: Enrollment in the expansion proof-of-concept study (PoC 2) was paused due to variability in early clinical outcomes. The company is reallocating resources to refine the clinical approach and plans to commence U.S.-based IDE clinical trials in late 2026, subject to financing.
• Regulatory Pathway: The company anticipates a De Novo classification process with the FDA, with potential regulatory clearance in the 2028 timeframe.

Material Risks and Contingencies

• Going Concern: The company has an accumulated deficit of $67.1 million and negative cash flows, raising substantial doubt about its ability to continue as a going concern without additional financing.
• Nasdaq Listing Compliance: The company received a deficiency letter from Nasdaq on January 14, 2026, for failing to maintain the minimum $1.00 bid price. It has until July 13, 2026, to regain compliance or risk delisting.
• Internal Controls: Management identified material weaknesses in internal controls over financial reporting, citing a lack of segregation of duties, general technology controls, and financial statement reporting issues.
• Manufacturing: The company relies on a single third-party manufacturer and has limited experience in commercial-scale assembly and testing.

Investor Verification Checklist

• Capital Raise Status: Verify if the company has secured the estimated $25–$32 million in additional financing required to reach commercial launch, given the "substantial doubt" regarding going concern status.
• Nasdaq Compliance: Monitor the stock price to determine if the company will regain compliance with the $1.00 minimum bid price requirement by July 13, 2026, or if a reverse stock split is implemented.
• Clinical Trial Progress: Confirm the status of the revised clinical protocol approved in April 2026 and the timeline for the commencement of U.S.-based IDE trials.
• Internal Control Remediation: Review subsequent filings for updates on the remediation of material weaknesses in internal controls over financial reporting.
• Warrant Dilution: Assess the potential dilution from the large number of outstanding warrants (over 10.7 million as of March 31, 2026) and their exercise terms.